# Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

> **NCT00410072** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 669 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Entecavir + Tenofovir

## Key facts

- **NCT ID:** NCT00410072
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2013-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410072, "Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00410072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*